MARKET

IPHA

IPHA

INNATE PHARMA SA
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.45
+0.25
+4.03%
Closed 16:00 07/02 EDT
OPEN
6.21
PREV CLOSE
6.20
HIGH
6.57
LOW
6.20
VOLUME
17.11K
TURNOVER
--
52 WEEK HIGH
8.24
52 WEEK LOW
3.300
MARKET CAP
506.84M
P/E (TTM)
-18.5451
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average IPHA stock price target is 12.00 with a high estimate of 17.50 and a low estimate of 8.50.

EPS

IPHA News

More
The Daily Biotech Pulse: MediciNova On Track For European Patent Win, Partial Clinical Hold Lifted For Innate Pharma, Tela Bio Details Coronavirus Impact
Benzinga · 06/24 13:07
Innate Pharma Earlier Announces FDA Lifts Partial Clinical Hold on Lacutamab TELLOMAK Trial in Advanced T-Cell Lymphomas
Benzinga · 06/24 12:34
U.S. Food and Drug Administration Lifts Partial Clinical Hold on Lacutamab TELLOMAK Trial in Advanced T-Cell Lymphomas
GlobeNewswire · 06/24 06:00
Chairman Powell Doesn't Have Whatever It Takes
Seeking Alpha - Article · 06/11 13:18
Charts Implying Economic Weakness - June 2020
Seeking Alpha - Article · 06/11 12:46
The Probability Of A U.S. Recession - June 2020
Seeking Alpha - Article · 06/10 15:24
Comprehensive Crude Tanker Supply Side Update
Seeking Alpha - Article · 06/09 13:01
Is Innate Pharma S.A. (IPHA) A Good Stock To Buy?
Insider Monkey · 05/31 03:47

Industry

Biotechnology & Medical Research
+0.68%
Pharmaceuticals & Medical Research
+0.61%

Hot Stocks

Symbol
Price
%Change

About IPHA

Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The Company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.
More

Webull offers kinds of Innate Pharma SA (ADR) stock information, including NASDAQ:IPHA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IPHA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IPHA stock methods without spending real money on the virtual paper trading platform.